MedTrace Logo

B-Cell Targeted Carfilzomib Desensitization

NCT02442648 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2020-06-30

No results posted yet for this study

Summary

The primary purpose of this study is to provide a preliminary evaluation of the safety and potential efficacy of carfilzomib in reducing HLA antibody levels in highly sensitized kidney transplant candidates.

Conditions

  • Transplants and Implants

Interventions

DRUG

Carfilzomib

Carfilzomib will be administered for desensitization per study protocol.

DRUG

Rituximab

Rituximab will be administered for desensitization per study protocol.

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • E. Steve Woodle

    lead OTHER

Principal Investigators

  • E. Steve Woodle, MD · University of Cincinnati

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2021-06-30
Completion
2021-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02442648 on ClinicalTrials.gov